Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$7.7 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$7.7 million, down 98.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.0 million (down 121.77% YoY), and the FY2025 annual result was -$21.2 million, down 89.66% from the prior year.
• Net Income towards Common Stockholders slipped to -$7.7 million in Q1 2026 per VVOS's latest filing, from -$7.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $9.4 million in Q4 2023 and troughed at -$7.7 million in Q1 2026.
• A 5-year average of -$3.8 million and a median of -$5.0 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders surged 253.83% in 2023, then slumped 159.74% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$6.1 million in 2022, then surged by 253.83% to $9.4 million in 2023, then tumbled by 130.8% to -$2.9 million in 2024, then sank by 141.04% to -$7.0 million in 2025, then dropped by 10.47% to -$7.7 million in 2026.
• Business Quant data shows VVOS's Net Income towards Common Stockholders at -$7.7 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.4 million in Q3 2025.